Drug Profile
Research programme: stem cell-based therapeutics - ViaCyte
Alternative Names: Pancreatic islet progenitor cells - ViaCyte; PEC-01™; Stem cell-derived pancreatic progenitor cells - ViaCyte; VC 03; VC 04Latest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator BetaLogics; ViaCyte Inc
- Developer University of California at San Francisco; ViaCyte Inc
- Class Stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (SC, Implant)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Parenteral)
- 26 May 2020 Preclinical development in Type-1 diabetes mellitus is ongoing in USA (SC, Implant)